Foghorn Therapeutics Inc. (FHTX) compared with its closest peers (BNTC, BIOA, AVIR, ENTA, RCKT). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Benitec Biopharma Inc. (BNTC) | $464.64M | -11.1 |
| BioAge Labs, Inc. (BIOA) | $435.33M | -5.9 |
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| Enanta Pharmaceuticals, Inc. (ENTA) | $390.28M | -2.8 |
| Rocket Pharmaceuticals, Inc. (RCKT) | $384.21M | -1.7 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $382.29M | -2.5 |
| Lyell Immunopharma, Inc. (LYEL) | $380.32M | -1.9 |
| Upstream Bio, Inc. (UPB) | $378.76M | -10.2 |
| Perspective Therapeutics, Inc. (CATX) | $376.70M | -2.0 |
| Galectin Therapeutics Inc. (GALT) | $372.64M | -8.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
FHTX overview · FHTX earnings · FHTX financials · FHTX KPIs · FHTX investor relations · FHTX ownership · FHTX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.